Victory Capital Management Inc. reduced its position in QIAGEN N.V. (NYSE:QGEN - Free Report) by 1.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,352,068 shares of the company's stock after selling 37,797 shares during the quarter. Victory Capital Management Inc. owned 1.06% of QIAGEN worth $94,436,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. raised its position in shares of QIAGEN by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company's stock worth $438,000 after acquiring an additional 341 shares in the last quarter. Pitcairn Co. raised its position in shares of QIAGEN by 5.3% in the 4th quarter. Pitcairn Co. now owns 6,996 shares of the company's stock worth $312,000 after acquiring an additional 354 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of QIAGEN by 2.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after acquiring an additional 395 shares in the last quarter. Headlands Technologies LLC increased its position in QIAGEN by 2.0% during the 4th quarter. Headlands Technologies LLC now owns 19,823 shares of the company's stock valued at $883,000 after buying an additional 397 shares in the last quarter. Finally, LPL Financial LLC increased its position in QIAGEN by 2.6% during the 4th quarter. LPL Financial LLC now owns 17,240 shares of the company's stock valued at $768,000 after buying an additional 432 shares in the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the company. Robert W. Baird raised their price objective on QIAGEN from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Redburn Atlantic downgraded QIAGEN from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Barclays initiated coverage on QIAGEN in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Wall Street Zen upgraded QIAGEN from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Finally, Bank of America increased their target price on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Seven equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $49.40.
Check Out Our Latest Report on QGEN
QIAGEN Price Performance
Shares of QIAGEN stock traded down $0.30 on Monday, hitting $48.06. The company's stock had a trading volume of 1,533,300 shares, compared to its average volume of 1,226,097. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $49.30. The company has a market capitalization of $10.68 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 2.46 and a beta of 0.68. The firm has a fifty day moving average price of $45.95 and a 200-day moving average price of $42.98.
QIAGEN (NYSE:QGEN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.05. QIAGEN had a return on equity of 14.61% and a net margin of 4.68%. The business had revenue of $483.46 million for the quarter, compared to analysts' expectations of $465.66 million. During the same period in the previous year, the firm posted $0.44 EPS. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.
QIAGEN Announces Dividend
The business also recently disclosed a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were given a dividend of $0.25 per share. This represents a dividend yield of 0.52%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's dividend payout ratio is currently 62.50%.
QIAGEN Profile
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
